Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lopinavir used for preparing medicine for guarding against or treating ischemic cardiovascular and cerebrovascular disease

A cardiovascular and cerebrovascular disease, ischemic technology, applied in the direction of cardiovascular system diseases, drug combination, pharmaceutical formula, etc., can solve the problem of prevention or treatment of ischemic cardiovascular and cerebrovascular diseases, pharmacological effects have not been reported, etc.

Inactive Publication Date: 2014-10-15
BINZHOU MEDICAL COLLEGE
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Clinically, the combination of lopinavir and ritonavir (trade name Kaletra) is used for the treatment of HIV / AIDS infection, and it can also be used in combination with other antiretroviral drugs for the treatment of HIV infection in adults and children over 6 months old , but the pharmacological effects of lopinavir in the prevention or treatment of ischemic cardiovascular and cerebrovascular diseases have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lopinavir used for preparing medicine for guarding against or treating ischemic cardiovascular and cerebrovascular disease
  • Lopinavir used for preparing medicine for guarding against or treating ischemic cardiovascular and cerebrovascular disease
  • Lopinavir used for preparing medicine for guarding against or treating ischemic cardiovascular and cerebrovascular disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of Lopinavir Tablets

[0013] Weigh 120.0g of lopinavir and 120.0g of carboxymethyl starch sodium, mix well and pass through a 100-mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to prepare soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, granulate with 18-mesh sieve, add 2.0g of magnesium stearate, mix evenly and press into tablets, adjust the weight of the tablet to about 240mg to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

The invention relates to the new application of medicine and particularly relates to lopinavir which can be used for guarding against or treating ischemic cardiovascular and cerebrovascular diseases through restraining the expression of HMG (High Mobility Group Protein) B1. According to the invention, the dosage range is 120 mg-6000 mg and 120-3000 mg of lopinavir is particularly preferred.

Description

technical field [0001] The invention relates to a new application of medicine, in particular to preventing or treating ischemic cardiovascular and cerebrovascular diseases by inhibiting the expression of HMGB1 with lopinavir. Background technique [0002] Ischemic stroke is a major disease that seriously endangers human health. Theoretical treatment methods include: (1) Thrombolytic therapy within 3-6 hours after onset. (2) Neuroprotective treatment of secondary nerve damage caused by ischemia. (3) Nerve repair promotes synaptic remodeling and regeneration of surviving nerve cells, including neuroregeneration and neurogenesis. Early thrombolytic therapy is currently recognized as the most effective method, but the treatment time window is narrow, and the indications must be strictly controlled. Currently, only about 3% to 5% of patients can receive thrombolytic therapy. Therefore, neuroprotection has become an important part of the treatment of ischemic stroke, which is d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/513A61P9/10A61P9/04
Inventor 蒋王林亢泽春徐洋纪云霞
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com